Redeye: Redeye Initiates Coverage of OncoZenge
Redeye initiates coverage of OncoZenge, a Swedish biotech company offering an innovative solution to the USD1.6bn oral mucositis treatment market. Bolstered by a strong ownership, a newly signed commercial partnership, and a de-risked pathway to the market, we see ample upside potential.
Read more and download the Research Report.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/